Skip to main content
MedPathMedPath Home
Clinical Trials/NL-OMON32559
NL-OMON32559
Not yet recruiting
Not Applicable

Routine manual hyperinflation versus on demand manual hyperinflation in intubated and mechanically ventilated post*cardiothoracic surgery patients * A randomized controlled trial * - Routine Manual Hyperinflation vs On Demand Manual Hyperinflation

Academisch Medisch Centrum0 sites100 target enrollmentTBD
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
ConditionsBaggingmanual ventilation10024970

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Bagging
Sponsor
Academisch Medisch Centrum
Enrollment
100
Status
Not yet recruiting
Last Updated
last year
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
last year
Study Type
Interventional

Investigators

Eligibility Criteria

Inclusion Criteria

  • •Patients planned for coronary artery bypass grafting and/or valve surgery are recruited
  • •\> 18 years of age
  • •written informed consent

Exclusion Criteria

  • •(Previous) pulmonary surgery
  • •Pulmonary infection

Outcomes

Primary Outcomes

Not specified

Similar Trials

Active, not recruiting
Not Applicable
A long term extension to a randomised, double-blind, placebo-controlled, stratified, paralle-group, multicenter, dose-ranging study evaluating four oral doses of TCH346 1.0, 2.5, 7.5 and 15 mg administered once daily in patients with Amyotrophic Lateral SclerosisAmyotrophic Lateral SclerosisMedDRA version: 9.1Level: LLTClassification code 10002026Term: Amyotrophic lateral sclerosis
EUCTR2004-002855-15-ITOVARTIS FARMA476
Completed
Phase 4
To evaluate the performance of Portico & Navitor heart Valve in Indian patientsHealth Condition 1: I350- Nonrheumatic aortic (valve) stenosis
CTRI/2022/04/041689Abbott India Pvt Ltd30
Active, not recruiting
Not Applicable
A long-term extension to a randomized, double-blind, placebo-controlled, stratified, parallel-group, multicenter, dose-ranging study evaluating four oral doses of TCH346 (1.0, 2.5, 7.5 and 15mg) administered once daily in patients with Amyotrophic Lateral Sclerosis.Amyotrophic Lateral Sclerosis
EUCTR2004-002855-15-DEovartis Pharma Services AG480
Active, not recruiting
Not Applicable
A long-term extension to a randomized, double-blind, placebo-controlled, stratified, parallel-group, multicenter, dose-ranging study evaluating four oral doses of TCH346 (1.0, 2.5, 7.5 and 15mg) administered once daily in patients with Amyotrophic Lateral Sclerosis.Amyotrophic Lateral Sclerosis
EUCTR2004-002855-15-GBovartis Pharma Services AG480
Active, not recruiting
Not Applicable
A randomised study comparing placebo and a not yet approved drug CS1008, in combination with drugs Carboplatin and Paclitaxel in patients with non small cell lung cancer which has spread or can not be removed by surgery, who have not had chemotherapy treatment before. The study is double-blind (that is when neither the patient nor the investigator know which treatment the patient is receiving).Treatment of metastatic or unresectable non small cell lung cancer (NSCLC) with CS 1008 or placebo first in combination with carboplatin/paclitaxel then as monotherapy in the first line settingMedDRA version: 14.0Level: PTClassification code 10059515Term: Non-small cell lung cancer metastaticSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 14.0Level: PTClassification code 10029522Term: Non-small cell lung cancer stage IVSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 14.0Level: PTClassification code 10029521Term: Non-small cell lung cancer stage IIIBSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)Therapeutic area: Diseases [C] - Cancer [C04]
EUCTR2007-004574-11-DEDaiichi Sankyo Development Limited120